This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (37)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

EDWARD D. FREIS, MD

Arch Intern Med. 1989;149(12):2640-2648.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

One of the disappointing conclusions of the antihypertensive drug trials is that, while most morbid events were prevented by treatment, the incidence of death from coronary heart disease (CHD) was not significantly reduced. As originally emphasized in the Veterans Administration trial¹ and in most subsequent trials, treatment has not resulted in a significant reduction in myocardial infarction (MI) and sudden death.

Various hypotheses have been advanced to explain the lack of benefit in the prevention of complications of coronary heart disease, including the following: (1) critical reduction of blood flow in the coronary arteries by lowering blood pressure too far with antihypertensive drugs; (2) initiation of treatment too late in patients with extensive coronary artery atherosclerosis; (3) failure to reduce other risk factors, such as diet and cigarette smoking; (4) inadequate length of follow-up to detect differences; and (5) use of drugs that may increase the risk of CHD . . . [Full Text PDF of this Article]

Author Affiliations
Veterans Administration Medical Center 50 Irving St NW Washington, DC 20815

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?